Crossject (ALCJ.PA) Aktsia Kursus
Crossject Kursus
Viimase 14 aasta jooksul kasvas Crossject käive 24,1 % aastas ja jõudis 4,12 M EUR-ni. Crossject netomarginaal −310,9 % on langenud võrreldes −203,2 %-ga mõni aasta tagasi. Crossject 12 kuu konsensuse hinnasiht on 4,39 EUR, umbes üle kurssi 213,3 %. 10 analüütikust 9 soovitab osta — üldine konsensus on Osta.
Crossject aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Crossject ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Crossject aktsia kohta
The business model of Crossject SA revolves around the development and commercialization of innovative drug delivery systems. Crossject specializes in needle-free, self-administered emergency treatments for severe medical conditions such as anaphylactic shock and epileptic seizures. The company's proprietary technology, Zeneo®, enables the rapid and efficient delivery of drugs through the skin, ensuring quick and reliable therapy in critical situations. By combining ease of use, portability, and safety, Crossject aims to revolutionize the field of self-medication. With a focus on achieving market penetration globally, Crossject collaborates with pharmaceutical companies to expand the range of emergency treatments available through its innovative delivery platform.
Crossject SA is primarily active in the pharmaceutical industry.
The main competitors of Crossject SA in the market include companies such as Pfizer, Novartis, Eli Lilly, Sanofi, and Johnson & Johnson.
Crossject SA is a renowned pharmaceutical company that specializes in developing innovative and efficient medical solutions. Founded in [year], the company is based in [location] and has a rich history of successful product development. Crossject SA primarily focuses on the development of advanced and easy-to-use medical injection systems, which aim to enhance patient convenience and treatment experiences. With a strong commitment to research and development, Crossject SA collaborates with experts in the healthcare industry to bring cutting-edge solutions to the market. The company has gained a reputation for its dedication to improving medical delivery methods, ensuring safer and more effective treatments for patients worldwide.
Crossject SA has achieved several significant milestones. The company successfully developed an innovative and proprietary needle-free injection system, Zeneo®. This device has the potential to revolutionize the way drugs are administered, providing numerous benefits such as painless injections, rapid drug delivery, and ease of use. Furthermore, Crossject SA has obtained regulatory approval for Zeneo® in Europe and initiated partnerships with major pharmaceutical companies to develop and market various drugs using their advanced technology. These achievements highlight Crossject SA's commitment to revolutionizing drug delivery and position the company as a key player in the pharmaceutical industry.
Crossject SA is primarily present in France, its country of origin. As a biopharmaceutical company, it focuses on developing and commercializing innovative injectable drug device combinations. With its headquarters in Dijon, France, Crossject SA operates in the European Union and has a strong presence in other regions as well. Its mission is to improve the quality of life for patients through its needle-free injection technologies.
Crossject SA represents a set of core values and a corporate philosophy that aligns with their mission. Known for their innovative drug delivery solutions, Crossject SA emphasizes excellence, integrity, and patient-centricity. With a focus on developing needle-free injection systems, the company is committed to providing safe, convenient, and effective medical devices to improve patient outcomes. Crossject SA's corporate philosophy centers around technological advancement, collaboration, and market leadership. Through their dedication to research, development, and strategic partnerships, Crossject SA continues to push boundaries in the pharmaceutical industry, delivering innovative solutions and driving positive change for patients globally.
Analüütikud määravad Crossject aktsiale keskmiseks hinnasihi 4,11 EUR (mediaan: 4,39 EUR), mis on +226,5 % viimase hinna suhtes. Konsensus põhineb 10 analüütiku hinnangul.
10 analüütikut hindavad praegu Crossject aktsiat: 9 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Crossject teenib tulu 34,50 M EUR ja kasumit aktsia kohta −0,02 EUR.
Crossject aktsia (ALCJ.PA) on noteeritud 3 börsil, sh: Frankfurt (74C.F), Paris (ALCJ.PA).
Crossject SA is an innovative healthcare company based in France that specializes in the development and manufacturing of injectable drug systems. The company aims to create new solutions for fast, easy, and safe drug administration. Crossject has been listed on the stock market since 2014 and has branches in France, Switzerland, and the USA. The business model of Crossject is based on the development and commercialization of innovative autoinjectors that contribute to improving the treatment of chronic and acute diseases. The company focuses on four main areas: diabetes, anaphylaxis, pain management, and emergency medicine. Crossject is currently developing a range of products in these areas that meet the requirements of patients, doctors, and hospitals. The products offered by Crossject include the ZMI Autoinjector System, the ZENEO Autoinjector System, and the COLLECTJECT Autoinjector System. The ZMI Autoinjector System is an easy-to-use system that administers medications in precise doses. This system is ideal for diabetics and provides a fast and effective solution for insulin administration. The ZENEO Autoinjector System has been specifically designed for use in patients with anaphylaxis. It is easy to use and provides fast and precise administration of adrenaline. The COLLECTJECT Autoinjector System is a disposable autoinjector specifically designed for emergencies. It can be used to administer various medications such as painkillers and antibiotics. Crossject's core competence is its proprietary Needle Free Injection technology, which allows for the administration of medications without penetrating the skin with a needle. This technology is not only efficient and painless, but also reduces the risk of needlestick injuries and infections. Crossject has successfully integrated this technology into its autoinjectors and is currently able to offer a variety of medications in injectable form. Crossject has developed a comprehensive strategy for the commercialization of its autoinjectors. The company works closely with its customers to better understand the needs of patients and doctors and adapt its products accordingly. Crossject has also formed partnerships with major pharmaceutical companies such as Sanofi and CDM Lavoisier to market its products and build a global presence. Overall, Crossject's business model demonstrates that the company is innovative and focused on the needs of patients and doctors. Crossject aims to revolutionize the healthcare industry through the development of new autoinjectors and the introduction of new medications. The company also strives to expand its global presence and strengthen its partnerships with pharmaceutical companies to better market its products.
oodatav Crossject käive on 34,50 M EUR. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Crossject kasum on −827 310,70 EUR. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Crossject jaoks on praegu −88,44. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Crossject aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Crossject jaoks on praegu 2,12. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Crossject aktsia jaoks.
Eulpooli kvaliteedinäitaja Crossject jaoks on 4/10.
Crossject ISIN on FR0011716265. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Crossject WKN on A1XEH4. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Crossject ticker on ALCJ.PA. Ticker-sümbol kasutatakse Crossject aktsiate kauplemiseks börsil.
Crossject aktsia
Kõik teised näitajad ja analüüsid Crossject kohta sügavamalt
Meie Crossject-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Crossject. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: